SCHEMBL3488705

SCHEMBL3488705

Cc1ccc(F)cc1Oc1ccc([N+](=O)[O-])c(CNC(=O)O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
MAPK1 P28482 3/20 0.47
HTT P42858 2/20 0.47
ALDH1A1 P00352 6/20 0.42
MAPT P10636 5/20 0.42
KMT2A Q03164 5/20 0.42
MEN1 O00255 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
LMNA P02545 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
HTR2A P28223 2/20 0.42
SLC6A4 P31645 2/20 0.42
KCNH2 Q12809 2/20 0.42
PKM P14618 1/20 0.42
HSPB1 P04792 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SNCA P37840 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3488709 1.00 SMN1; SMN2 (0.47) SMN1; SMN2MAPK1HTTALDH1A1MAPT
SCHEMBL3487480 0.91 MAPK1 (0.45) SMN1; SMN2MAPK1HTTALDH1A1MAPT
SCHEMBL3487488 0.91 MAPK1 (0.45) SMN1; SMN2MAPK1HTTALDH1A1MAPT
SCHEMBL3487353 0.90 MAPK1 (0.46) SMN1; SMN2MAPK1HTTALDH1A1MAPT
SCHEMBL3487345 0.90 MAPK1 (0.46) SMN1; SMN2MAPK1HTTALDH1A1MAPT
SCHEMBL3487910 0.89 HSPB1 (0.46) SMN1; SMN2MAPK1HTTALDH1A1MAPT
SCHEMBL3487917 0.89 HSPB1 (0.46) SMN1; SMN2MAPK1HTTALDH1A1MAPT
SCHEMBL3487468 0.85 MEN1 (0.42) SMN1; SMN2MAPK1HTTALDH1A1MAPT
SCHEMBL3487476 0.85 MEN1 (0.42) SMN1; SMN2MAPK1HTTALDH1A1MAPT
SCHEMBL3487363 0.84 HSPB1 (0.45) SMN1; SMN2MAPK1HTTALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA SMN1; SMN2 4397/4885MAPK1 1347/4885HTT 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.